B.J. Rimel

6.4k citations

113 papers · 2.6k indexed · 2 hit papers · h-index 23

Impact in

Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment
Oncology top 2%
- PARP inhibition in cancer therapy
- Cancer survivorship and care

Papers in

Reproductive Medicine 57
- Ovarian cancer diagnosis and treatment 52
- Endometriosis Research and Treatment 8
Obstetrics and Gynecology 21
- Endometrial and Cervical Cancer Treatments 21

Co-authors: Ursula A. Matulonis Gini F. Fleming Beth Y. Karlan Christine Walsh Ilana Cass Elise C. Kohn Jean Hurteau Mary K. Buss
Journals: Gynecologic Oncology (41 papers)Journal of Clinical Oncology (15 papers)Annals of Oncology (6 papers)Cancer (3 papers)International Journal of Gynecological Cancer (2 papers)
Partner nations: United States Canada Spain

In The Last Decade

B.J. Rimel

108 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial 2019 · 377 citations

Peers

Countries citing papers authored by B.J. Rimel

Since Specialization

Citations

This map shows the geographic impact of B.J. Rimel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.J. Rimel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.J. Rimel more than expected).

Fields of papers citing papers by B.J. Rimel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.J. Rimel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.J. Rimel. The network helps show where B.J. Rimel may publish in the future.

Co-authors

The 25 scholars most cited alongside B.J. Rimel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with B.J. Rimel Line = papers co-authored together B.J. Rimel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers Gynecologic Oncology Reports ·Bhavana Pothuri, 毕正绪, Ming Liu, John U. Farley, 幸広福田, Summer Dewdney, Fangying Pei Fangying Pei, John Chan, Sharad Ghamande, Asma Farhan Al Asharab, Marina Stasenko, B.J. Rimel, Electra D. Paskett	2025	0
2	What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice? Gynecologic Oncology ·Linda Duska, Maureen Cooney, Zsófia Kiss, 毛维浩, Amanda Golembesky, Jeanne M. Schilder, Ming Liu, N.T. Chen, Jinlin Song, Teruhisa Ando, 邦幸高橋, B.J. Rimel	2024	1
3	Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting Gynecologic Oncology Reports ·B.J. Rimel, Dana M. Chase, Fady Zakar, Armen A. Ghazarian, Ella X. Du, Flor de Maria Araújo Mendonça Silva, Jinlin Song, Amanda Golembesky, Jean Hurteau, Linda Kalilani, Ritu Salani, Bradley J. Monk	2024	3
4	Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200) Gynecologic Oncology ·Dana M. Chase, B.J. Rimel, Fady Zakar, Armen A. Ghazarian, Ella X. Du, Flor de Maria Araújo Mendonça Silva, Jinlin Song, Amanda Golembesky, Jean Hurteau, Ritu Salani, Bradley J. Monk	2023	1
5	NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer Cancer ·B.J. Rimel, Danielle Enserro, David Bender, Veena Prabhakaran, Annie Tan, Henry W. Slesser, Mark E. Borowsky, John W. Moroney, Andrea Wahner Hendrickson, Floor Backes, Elizabeth M. Swisher, Matthew A. Powell, Helen Mackay	2023	6
6	Vaginal Cuff Dehiscence in Transgender Patients After Minimally Invasive Hysterectomy Journal of Minimally Invasive Gynecology ·Reed M. O’Connor, Kaz Kobayashi, B.J. Rimel	2023	2
7	Sexual orientation and gender identity inequities in cervical cancer screening by race and ethnicity Cancer Causes & Control ·正川島, Hai ZHANG, B.J. Rimel, Jarvis T. Chen, D. Linnarson, Geetanjali D. Datta	2023	8
8	Safety and management of niraparib monotherapy in ovarian cancer clinical trials International Journal of Gynecological Cancer ·Bradley J. Monk, Antonio González-Martı́n, Lynn Buckley, Ursula A. Matulonis, B.J. Rimel, Xiaohua Wu, Kathleen N. Moore, Mansoor Raza Mirza	2023	18
9	Inequities in colorectal and breast cancer screening: At the intersection of race/ethnicity, sexuality, and gender SSM - Population Health ·正川島, Hai ZHANG, B.J. Rimel, Geetanjali D. Datta	2023	6
10	Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations Gynecologic Oncology ·B.J. Rimel, Erin K. Crane, June Y. Hou, John Nakayama, Jennifer MacDonald, Martina Eckey-Knobloch, Vicky Makker, Roisin E. O’Cearbhaill	2023	6
11	Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects Cancer Research Communications ·Mansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, Andrés Redondo, Michel Fabbro, B.J. Rimel, Jørn Herrstedt, Amit M. Oza, Ulrich Canzler, Jonathan S. Berek, Antonio González-Martı́n, Yasuhide Abe, Rosemary Lord, Masoud Azodi, Constance Anne Bak, Zebin Wang, Yong Li, Divya Gupta, Ursula A. Matulonis, Bin Feng	2022	5
12	Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination Cancer Research ·L.X. Zhang, Vinod Pant, Amanda R. Wasylishen, B.J. Rimel, Laura Baseler, Adel K. El‐Naggar, David G. Mutch, Paul J. Goodfellow, Swathi Arur, Guillermina Lozano	2019	12
13	Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients npj Digital Medicine ·Gillian Gresham, Andrew Hendifar, Brennan Spiegel, Elad Neeman, Richard Tuli, B.J. Rimel, Robert A. Figlin, Curtis L. Meinert, Steven Piantadosi, A. Shinde	2018	117
14	An educational intervention to improve human papilloma virus (HPV) and cervical cancer knowledge among African American college students Gynecologic Oncology ·韦怡汪, Melissa S. Wong, B.J. Rimel	2018	30
15	The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial Annals of Oncology ·F S Guzmán Yunqué, Katherine E. Richardson, Mansoor Raza Mirza, Lucy Gilbert, Michel Fabbro, Anna V. Tinker, Rose Shayo, Andrés Redondo, J. S. Berek, Linn Woelber, Helen S. Pentikis, Kathleen N. Moore, Domenica Lorusso, Benedict B. Benigno, Sebastien Hazard, Philippe Follana, B.J. Rimel, Ursula A. Matulonis, Shefali Agarwal, Vikram Kansra	2017	8
16	Wearable activity monitors in oncology trials: Current use of an emerging technology Contemporary Clinical Trials ·Gillian Gresham, Jennifer A. Schrack, Esther Los, A. Shinde, Andrew Hendifar, Richard Tuli, B.J. Rimel, Robert A. Figlin, Curtis L. Meinert, Steven Piantadosi	2017	100
17	gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial) Annals of Oncology ·Mansoor Raza Mirza, Bradley J. Monk, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, JA Ledermann, Domenica Lorusso, Ignace Vergote, Ora Rosengarten, J. S. Berek, Jørn Herrstedt, 則男宮原, Andreas duBois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, B.J. Rimel, Shefali Agarwal, Ursula A. Matulonis	2016	7
18	Clinical Trial Accrual: Obstacles and Opportunities Frontiers in Oncology ·B.J. Rimel	2016	15
19	Statin use and survival in elderly patients with endometrial cancer Gynecologic Oncology ·Liyun ZHONG, Marc T. Goodman, B.J. Rimel, Christie Y. Jeon	2015	26
20	Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival Gynecologic Oncology ·Joshua G. Cohen, Albano Wascura, B.J. Rimel, Ilana Cass, Christine Walsh, Beth Y. Karlan, Andrew J. Li	2014	29

About B.J. Rimel

B.J. Rimel is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Cancer Research and Genetics, having authored 113 papers that have together received 2.6k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (52 papers), PARP inhibition in cancer therapy (32 papers), Endometrial and Cervical Cancer Treatments (21 papers), BRCA gene mutations in cancer (16 papers), Cervical Cancer and HPV Research (12 papers), Endometriosis Research and Treatment (8 papers), Global Cancer Incidence and Screening (8 papers) and Cancer Genomics and Diagnostics (7 papers). The work is most often cited by research in Reproductive Medicine (1.1k citations), Oncology (1.4k citations), Obstetrics and Gynecology (369 citations), Virology (79 citations) and Cancer Research (237 citations). B.J. Rimel has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Ursula A. Matulonis, Gini F. Fleming, Beth Y. Karlan, Christine Walsh, Ilana Cass, Elise C. Kohn, Jean Hurteau, Mary K. Buss, Ronald J. Buckanovich and S. Percy Ivy. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, Annals of Oncology, Cancer and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact